首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1724763

全球流感市場

The Global Influenza Market

出版日期: 2025年05月06日 | 出版商:

BCC Research | 英文 188 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球流感市場規模預計將從 2024 年的 90 億美元成長到 2029 年底的 128 億美元，在 2024-2029 年預測期內的複合年成長率為 7.2%。

預計北美市場將從 2024 年的 45 億美元擴大到 2029 年的 63 億美元，同期的複合年成長率為 7.3%。預計 2024 年歐洲市場價值將達到 24 億美元，到 2029 年將達到 33 億美元，複合年成長率為 6.8%。

本報告調查了全球流感市場，並提供了市場概況的摘要、市場影響因素和市場機會的分析、法律制度、新興技術和技術發展的趨勢、市場規模的趨勢和預測、各個細分市場和地區的詳細分析、競爭格局以及主要企業的概況。

市場動態
關鍵要點
市場促進因素
快速檢測和分子技術的開發
政府對新治療方法和診斷方法的支持和資助
提高大眾對流感疫苗的認知
市場限制
治療市場由有限數量的供應商主導
儲存和分發流感疫苗的高成本
市場機會
強大的流感疫苗研發管道
呼籲改善預防、治療和疫苗的取得途徑

第4章監管情況

概述
流感疫苗法規
美國流感季節的三價疫苗
EMA核准的流感疫苗
流感治療藥物的監管現狀
流感檢測套件的核准流程
敏感度
特異性

第5章新興趨勢與通路分析

概述
流感診斷進展
SHINE科技
電化學生物感測器
實驗室晶片設備
量子點和螢光奈米粒子
人工智慧在流感診斷中的作用
流感疫苗新技術
通用流感疫苗
基於mRNA的流感疫苗
基於奈米技術的疫苗
貼片疫苗
流感治療的進展
基於奈米粒子的治療方法
臨床試驗中的潛在藥物
專利分析
關鍵要點

第6章市場區隔分析

細分市場
全球流感市場（按產品細分）
流感診斷
流感疫苗
流感藥物
地理分佈
關鍵要點
北美洲
歐洲
亞太地區
其他

第7章競爭訊息

流感疫苗市場企業市場占有率分析
流感診斷市場企業市場占有率分析
流感治療藥物市場企業市場占有率分析
創業融資與投資格局
主要市場發展

第8章流感市場的永續性：ESG 視角

概述
ESG風險評估
結論

第9章附錄

調查方法
來源
簡稱
公司簡介
ABBOTT
ASTRAZENECA
BD
BIOCRYST PHARMACEUTICALS INC.
CSL
DAIICHI SANKYO CO. LTD.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC.
HOLOGIC INC.
QUIDELORTHO CORP.
SANOFI
SEKISUI DIAGNOSTICS
THERMO FISHER SCIENTIFIC INC.
VIATRIS INC.
新興Start-Ups/市場顛覆者

簡介目錄圖表

Product Code: PHM049F

The global influenza market is expected to grow from $9.0 billion in 2024 and is projected to reach $12.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.2% during the forecast period of 2024 to 2029.

The North American influenza market is expected to grow from $4.5 billion in 2024 and is projected to reach $6.3 billion by the end of 2029, at a CAGR of 7.3% during the forecast period of 2024 to 2029.

The European influenza market is expected to grow from $2.4 billion in 2024 and is projected to reach $3.3 billion by the end of 2029, at a CAGR of 6.8% during the forecast period of 2024 to 2029.

Report Scope

This report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and diagnostics.

Analyses of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions-North America, Europe and Asia-Pacific-and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also discussed.

The market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every region.

For market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through 2029.

Report Includes

55 data tables and 70 additional tables
An updated overview and in-depth analysis of the global influenza market
Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029
Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region
Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV)
Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors
Insight into the influenza industry structure, government regulations, and key development issues
Analysis of the key patent grants and IP aspects
A discussion of the industry's ESG challenges and practices of the industry
Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares
Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Overview
Pandemic Scenario
Porter's Five Forces Analysis in the Influenza Vaccines Market
Potential of New Entrants (Moderate)
Bargaining Power of Suppliers (Moderate)
Bargaining Power of Buyers (Moderate to High)
Threat of Substitute Products or Services (Moderate)
Industry Rivalry (High)
Supply Chain Analysis
Vaccine Development
Vaccine Manufacturing
Storage and Inventory Management
Distribution
Administration and Immunization
Macroeconomic Factors Analysis
Impact of U.S.-China Trade War
Global Economic Growth
Demographic Trends
Public Health Crises and Pandemics

Chapter 3 Market Dynamics

Market Dynamics
Key Takeaways
Market Drivers
Development of Rapid Tests and Molecular Technologies
Government Support and Funding for Novel Therapies and Diagnosis
Rising Public Awareness About Flu Vaccines
Market Restraints
Therapeutic Market Dominated by Limited Suppliers
High Cost Associated with Storage and Supply of Flu Vaccines
Market Opportunities
Robust Pipeline of Influenza Vaccines
Demand for Improved Prevention, Treatment and Vaccine Accessibility

Chapter 4 Regulatory Landscape

Overview
Regulatory Aspects of Influenza Vaccines
Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season
Influenza Vaccines Approved by EMA
Regulatory Scenario of Influenza Drugs
Approval Process of Influenza Detection Kit
Sensitivity
Specificity

Chapter 5 Emerging Trends and Pipeline Analysis

Overview
Advance in Influenza Diagnosis
SHINE Technology
Electrochemical Biosensors
Wearable Lab-on-a-Chip Devices
Quantum Dots and Fluorescent Nanoparticles
Role of AI in Influenza Diagnosis
Emerging Technologies in Influenza Vaccines
Universal Influenza Vaccine
mRNA-based Influenza Vaccines
Nanotechnology-based Vaccines
Patch-based Vaccines
Advances in Influenza Therapeutics
Nanoparticle-based Therapies
Potential Drug Agents in Clinical Trials
Patent Analysis
Key Takeaways

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Influenza Market by Product Segment
Influenza Diagnostics
Influenza Vaccines
Influenza Therapeutics
Geographic Breakdown
Key Takeaways
North America
Europe
Asia-Pacific
Rest of World

Chapter 7 Competitive Intelligence

Company Share Analysis of the Influenza Vaccines Market
Company Share Analysis of Influenza Diagnostics Market
Company Share Analysis of Influenza Therapeutics Market
Venture Fundings and Investments Landscape
Key Developments in Market

Chapter 8 Sustainability in Influenza Market: ESG Perspective

Overview
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Sources
Abbreviations
Company Profiles
ABBOTT
ASTRAZENECA
BD
BIOCRYST PHARMACEUTICALS INC.
CSL
DAIICHI SANKYO CO. LTD.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
GSK PLC.
HOLOGIC INC.
QUIDELORTHO CORP.
SANOFI
SEKISUI DIAGNOSTICS
THERMO FISHER SCIENTIFIC INC.
VIATRIS INC.
Emerging Start-ups/Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Influenza Market, by Region, Through 2029
Table 1 : History of Influenza Pandemics, 1729-2021
Table 2 : Confirmed Cases of Influenza, 2022-2024
Table 3 : Influenza Vaccines in Clinical Trials, 2024
Table 4 : Vaccines Licensed for Use in the U.S., 2024
Table 5 : FDA-Approved Influenza Drugs, 1966-2018
Table 6 : Approved Influenza Drugs in Other Countries
Table 7 : FDA-Approved Influenza Detection Tests, 2024
Table 8 : List of Vaccine Pipelines for Influenza Virus-based Platform, 2024
Table 9 : List of Vaccine Pipelines for Non-VLP Nanoparticles Platform, 2024
Table 10 : List of Vaccine Pipelines for Nucleic Acid-based Platform, 2024
Table 11 : List of Vaccine Pipelines for Recombinant Proteins Platform, 2024
Table 12 : List of Vaccine Pipelines for Virus-like particles (VLP) Platform, 2024
Table 13 : List of Vaccine Pipelines for Virus-vectored Platform, 2024
Table 14 : Influenza Drugs in Clinical Trials, 2024
Table 15 : List of Several Granted Patents in Influenza Vaccine, 2023-2025
Table 16 : List of Several Granted Patents in Influenza Diagnosis Tools, 2023-2025
Table 17 : List of Several Granted Patents in Influenza Drugs, 2023-2025
Table 18 : Global Influenza Market, by Product Segment, Through 2029
Table 19 : Global Influenza Diagnostics Market, by Type, Through 2029
Table 20 : Influenza Virus Testing Methods, 2024
Table 21 : FDA-Approved Influenza Detection Devices, 2022-2025
Table 22 : Global Influenza Diagnostics Market, by Region, Through 2029
Table 23 : Influenza Vaccine Products for the 2024-2025 Influenza Season
Table 24 : Global Influenza Vaccines Market, by Type, Through 2029
Table 25 : Seasonal Influenza Vaccines Pricing, 2024-2025
Table 26 : Global Influenza Vaccines Market, by Region, Through 2029
Table 27 : Global Influenza Therapeutics Market, by Region, Through 2029
Table 28 : Global Influenza Market, by Region, Through 2029
Table 29 : North American Influenza Market, by Product Segment, Through 2029
Table 30 : North American Influenza Market, by Country, Through 2029
Table 31 : Results of Tests Performed by Clinical Laboratories in the U.S., 2020-2024
Table 32 : Results of Tests Performed by Clinical Laboratories in the U.S., 2024-2025 Season
Table 33 : The U.S. Influenza Market, by Product Segment, Through 2029
Table 34 : Number of Influenza Detection in Canada, by Age Group, 2024-2025 Season
Table 35 : Canadian Influenza Market, by Product Segment, Through 2029
Table 36 : Influenza Vaccination Coverage in Mexico, 2018-2023
Table 37 : Mexican Influenza Market, by Product Segment, Through 2029
Table 38 : European Influenza Market, by Product Segment, Through 2029
Table 39 : European Influenza Market, by Country, Through 2029
Table 40 : Influenza Vaccination Coverage in Germany, 2018-2023
Table 41 : German Influenza Market, by Product Segment, Through 2029
Table 42 : Vaccines Marketed in U.K. for 2024-2025 Influenza Season
Table 43 : Influenza Vaccination Coverage in U.K., 2018-2023
Table 44 : U.K. Influenza Market, by Product Segment, Through 2029
Table 45 : Influenza Vaccination Coverage in France, 2018-2023
Table 46 : French Influenza Market, by Product Segment, Through 2029
Table 47 : Influenza Vaccines for Use in Pediatrics in Spain, 2024-2025 Season
Table 48 : Spanish Influenza Market, by Product Segment, Through 2029
Table 49 : Italian Influenza Market, by Product Segment, Through 2029
Table 50 : Rest of European Influenza Market, by Product Segment, Through 2029
Table 51 : Asia-Pacific Influenza Market, by Product Segment, Through 2029
Table 52 : Asia-Pacific Influenza Market, by Country, Through 2029
Table 53 : Chinese Influenza Market, by Product Segment, Through 2029
Table 54 : Japanese Influenza Market, by Product Segment, Through 2029
Table 55 : Indian Influenza Market, by Product Segment, Through 2029
Table 56 : Australian Influenza Market, by Product Segment, Through 2029
Table 57 : Rest of Asia-Pacific Influenza Market, by Product Segment, Through 2029
Table 58 : Rest of World Influenza Market, by Product Segment, Through 2029
Table 59 : Rest of World Influenza Market, by Country, Through 2029
Table 60 : South American Influenza Market, by Product Segment, Through 2029
Table 61 : Middle Eastern and African Influenza Market, by Product Segment, Through 2029
Table 62 : Recent Venture Fundings in the Influenza Market, 2024
Table 63 : Recent Key Developments in Influenza Market, 2023 and 2024
Table 64 : ESG Risk Rankings for Influenza Market Companies, 2025*
Table 65 : Report Information Sources
Table 66 : Abbreviations Used in the Global Influenza Market
Table 67 : Abbott: Company Snapshot
Table 68 : Abbott: Financial Performance, FY 2022 and 2023
Table 69 : Abbott: Product Portfolio
Table 70 : Abbott: News/Key Developments, 2024
Table 71 : AstraZeneca: Company Snapshot
Table 72 : AstraZeneca: Financial Performance, FY 2022 and 2023
Table 73 : AstraZeneca: Product Portfolio
Table 74 : AstraZeneca: News/Recent Developments, 2023 and 2024
Table 75 : BD: Company Snapshot
Table 76 : BD: Financial Performance, FY 2022 and 2023
Table 77 : BD: Product Portfolio
Table 78 : BD: News/Key Developments, 2021-2023
Table 79 : BioCryst Pharmaceuticals Inc.: Company Snapshot
Table 80 : BioCryst Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 81 : BioCryst Pharmaceuticals Inc.: Product Portfolio
Table 82 : CSL: Company Snapshot
Table 83 : CSL: Financial Performance, FY 2022 and 2023
Table 84 : CSL: Product Portfolio
Table 85 : CSL: News/Key Developments, 2022-2024
Table 86 : Daiichi Sankyo Co. Ltd.: Company Snapshot
Table 87 : Daiichi Sankyo Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 88 : Daiichi Sankyo Co. Ltd.: Product Portfolio
Table 89 : Daiichi Sankyo Co. Ltd.: News/Key Developments, 2023
Table 90 : Danaher Corp.: Company Snapshot
Table 91 : Danaher Corp.: Financial Performance, FY 2022 and 2023
Table 92 : Danaher Corp.: Product Portfolio
Table 93 : Danaher Corp: News/Recent Developments, 2021 and 2022
Table 94 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 95 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 96 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 97 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2024
Table 98 : GSK Plc.: Company Snapshot
Table 99 : GSK Plc.: Financial Performance, FY 2022 and 2023
Table 100 : GSK Plc.: Product Portfolio
Table 101 : GSK Plc.: News/Key Developments, 2024
Table 102 : Hologic Inc.: Company Snapshot
Table 103 : Hologic Inc.: Financial Performance, FY 2022 and 2023
Table 104 : Hologic Inc.: Product Portfolio
Table 105 : Hologic Inc.: News/Key Developments, 2022
Table 106 : QuidelOrtho Corp.: Company Snapshot
Table 107 : QuidelOrtho Corp.: Financial Performance, FY 2022 and 2023
Table 108 : QuidelOrtho Corp.: Product Portfolio
Table 109 : QuidelOrtho Corp.: News/Key Developments, 2024
Table 110 : Sanofi: Company Snapshot
Table 111 : Sanofi: Financial Performance, FY 2022 and 2023
Table 112 : Sanofi: Product Portfolio
Table 113 : Sanofi: News/Key Developments, 2022-2024
Table 114 : Sekisui Diagnostics: Company Snapshot
Table 115 : Sekisui Diagnostics: Product Portfolio
Table 116 : Sekisui Diagnostics: News/Key Developments, 2024
Table 117 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 118 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 119 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 120 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023
Table 121 : Viatris Inc.: Company Snapshot
Table 122 : Viatris Inc.: Financial Performance, FY 2022 and 2023
Table 123 : Viatris Inc.: Product Portfolio
Table 124 : List of Selected Emerging Startups

List of Figures

Summary Figure : Global Influenza Market Shares, by Region, 2023
Figure 1 : Porter's Five Forces Analysis of the Influenza Vaccines Market
Figure 2 : Supply Chain Analysis of Influenza Vaccine
Figure 3 : Market Dynamics of the Global Influenza Market
Figure 4 : Clinical Trial Studies of Influenza Vaccines, by Trial Phase, 2024
Figure 5 : Global Influenza Market Shares, by Product Segment, 2023
Figure 6 : Global Influenza Diagnostics Market Shares, by Type, 2023
Figure 7 : FDA-Approval of Influenza Detection Devices, 2015-January 2025
Figure 8 : Global Influenza Diagnostics Market Shares, by Region, 2023
Figure 9 : Global Influenza Vaccines Market Shares, by Type, 2023
Figure 10 : Global Influenza Vaccines Market Shares, by Region, 2023
Figure 11 : Global Influenza Therapeutics Market Shares, by Region, 2023
Figure 12 : Global Influenza Market Shares, by Region, 2023
Figure 13 : North American Influenza Market Shares, by Product Segment, 2023
Figure 14 : North American Influenza Market Shares, by Country, 2023
Figure 15 : Total Vaccine Doses Distributed in U.S., 2008-2023
Figure 16 : Influenza-Positive Tests Reported to the CDC by U.S. Clinical Laboratories, 2024-2025 Season
Figure 17 : The U.S. Influenza Market Shares, by Product Segment, 2023
Figure 18 : Influenza Detection in Canada, by Age Group and Report Week, 2024-2025 Season
Figure 19 : Canadian Influenza Market Shares, by Product Segment, 2023
Figure 20 : Mexican Influenza Market Shares, by Product Segment, 2023
Figure 21 : European Influenza Market Shares, by Product Segment, 2023
Figure 22 : European Influenza Market Shares, by Country, 2023
Figure 23 : German Influenza Market Shares, by Product Segment, 2023
Figure 24 : U.K. Influenza Market Shares, by Product Segment, 2023
Figure 25 : French Influenza Market Shares, by Product Segment, 2023
Figure 26 : Spanish Influenza Market Shares, by Product Segment, 2023
Figure 27 : Italian Influenza Market Shares, by Product Segment, 2023
Figure 28 : Rest of European Influenza Market Shares, by Product Segment, 2023
Figure 29 : Asia-Pacific Influenza Market Shares, by Product Segment, 2023
Figure 30 : Asia-Pacific Influenza Market Shares, by Country, 2023
Figure 31 : Chinese Influenza Market Shares, by Product Segment, 2023
Figure 32 : Japanese Influenza Market Shares, by Product Segment, 2023
Figure 33 : Indian Influenza Market Shares, by Product Segment, 2023
Figure 34 : Australian Influenza Market Shares, by Product Segment, 2023
Figure 35 : Rest of Asia-Pacific Influenza Market Shares, by Product Segment, 2023
Figure 36 : Rest of World Influenza Market Shares, by Product Segment, 2023
Figure 37 : Rest of World Influenza Market Shares, by Country, 2023
Figure 38 : South American Influenza Market Shares, by Product Segment, 2023
Figure 39 : Middle Eastern and African Influenza Market Shares, by Product Segment, 2023
Figure 40 : Company Share Analysis of Influenza Vaccine Market, 2023
Figure 41 : Company Share Analysis of Influenza Diagnostics Market, 2023
Figure 42 : Company Share Analysis of Influenza Therapeutics Market, 2023
Figure 43 : Abbott: Revenue Shares, by Business Unit, FY 2023
Figure 44 : Abbott: Revenue Shares, by Country/Region, FY 2023
Figure 45 : AstraZeneca: Revenue Shares, by Business Unit, FY 2023
Figure 46 : AstraZeneca: Revenue Shares, by Region/Country, FY 2023
Figure 47 : BD: Revenue Shares, by Business Unit, FY 2023
Figure 48 : BD: Revenue Shares, by Country/Region, FY 2023
Figure 49 : BioCryst Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 50 : BioCryst Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 51 : CSL: Revenue Shares, by Business Unit, FY 2023
Figure 52 : CSL: Revenue Shares, by Country/Region, FY 2023
Figure 53 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 54 : Daiichi Sankyo Co. Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 55 : Danaher Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 56 : Danaher Corp.: Revenue Shares, by Region/Country, FY 2023
Figure 57 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 58 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 59 : GSK Plc.: Revenue Shares, by Business Unit, FY 2023
Figure 60 : GSK Plc.: Revenue Shares, by Country/Region, FY 2023
Figure 61 : Hologic Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 62 : Hologic Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 63 : QuidelOrtho Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 64 : QuidelOrtho Corp.: Revenue Shares, by Country/Region, FY 2023
Figure 65 : Sanofi: Revenue Shares, by Business Unit, FY 2023
Figure 66 : Sanofi: Revenue Shares, by Country/Region, FY 2023
Figure 67 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 68 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 69 : Viatris Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 70 : Viatris Inc.: Revenue Shares, by Country/Region, FY 2023